Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30260039 | 1.00 | MEN1 (0.31) | MEN1POLBHPGDALOX12KMT2A | |
| SCHEMBL24425031 | 0.86 | — | — | |
| SCHEMBL25165297 | 0.86 | — | — | |
| SCHEMBL24424954 | 0.77 | KDM4E (0.33) | MEN1KMT2AALDH1A1 | |
| SCHEMBL24778050 | 0.75 | L3MBTL1 (0.33) | ALDH1A1 | |
| SCHEMBL25805536 | 0.75 | ALDH1A1 (0.44) | MEN1POLBHPGDALOX12KMT2A | |
| SCHEMBL25805404 | 0.75 | L3MBTL1 (0.34) | MEN1POLBHPGDALOX12KMT2A | |
| SCHEMBL29654317 | 0.75 | TLR9 (0.35) | — | |
| SCHEMBL18128520 | 0.74 | ALDH1A1 (0.31) | HPGDKMT2AALDH1A1 | |
| SCHEMBL31521270 | 0.74 | KHK (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790059-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-118556063-A | Heterocyclic compound, pharmaceutical composition and application thereof | 上海湃隆生物科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024046370-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITORS, AND PREPARATION AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-03-07 | — | — | WO | disclosed |
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023138583-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | MEN1 226/4885POLB 589/4885HPGD 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.